Type 2 Diabetes Mellitus Duration and Obesity alter the Efficacy of Autologously Transplanted Bone Marrow-derived Mesenchymal Stem/Stromal Cells
(2021)
Journal Article
Nguyen, L. T., Hoang, D. M., Nguyen, K. T., Bui, D. M., Nguyen, H. T., Le, H. T., Hoang, V. T., Bui, H. T., Dam, P. T., Hoang, X. T., Ngo, A. T., Le, H. M., Phung, N. Y., Vu, D. M., Duong, T. T., Nguyen, T. D., Ha, L. T., Bui, H. T., Nguyen, H. K., Heke, M., & Bui, A. V. (2021). Type 2 Diabetes Mellitus Duration and Obesity alter the Efficacy of Autologously Transplanted Bone Marrow-derived Mesenchymal Stem/Stromal Cells. Stem Cells Translational Medicine, 10(9), 1266-1278. https://doi.org/10.1002/sctm.20-0506
Human bone marrow-derived mesenchymal stem/stromal cells (BM-MSCs) represent promising stem cell therapy for the treatment of type 2 diabetes mellitus (T2DM), but the results of autologous BM-MSC administration in T2DM patients are contradictory. The... Read More about Type 2 Diabetes Mellitus Duration and Obesity alter the Efficacy of Autologously Transplanted Bone Marrow-derived Mesenchymal Stem/Stromal Cells.